Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Cancer Immunotherapy Drugs Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in prevalence of cancer across the world
5.1.1.2. Growing adoption of immunotherapy over other treatments
5.1.1.3. Developments of bioinformatics tools and resources for cancer immunotherapy study
5.1.2. Restraints
5.1.2.1. High cost of therapy and unpredictable effectiveness of immuno-oncology agents
5.1.3. Opportunities
5.1.3.1. Recent developments in immunotherapy technologies
5.1.3.2. Significant investment and funding for immunotherapy research
5.1.4. Challenges
5.1.4.1. Possibilities of adverse effects of the available therapies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Cancer Immunotherapy Drugs Market, by Type
6.1. Introduction
6.2. Cancer Vaccines
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Monoclonal Antibodies

7. Cancer Immunotherapy Drugs Market, by Indication
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Head & Neck Cancer
7.5. Lung Cancer
7.6. Melanoma
7.7. Prostate Cancer

8. Cancer Immunotherapy Drugs Market, by End-user
8.1. Introduction
8.2. Ambulatory Surgical Center
8.3. Hospitals & Clinics

9. Americas Cancer Immunotherapy Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cancer Immunotherapy Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Cancer Immunotherapy Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie, Inc.
13.1.2. Amgen Inc.
13.1.3. Astellas Pharma Inc.
13.1.4. AstraZeneca PLC
13.1.5. Bayer AG
13.1.6. Boehringer Ingelheim International GmbH
13.1.7. Bristol Myers Squibb Company
13.1.8. CARsgen Therapeutics
13.1.9. Celldex Therapeutics, Inc.
13.1.10. ElevateBio
13.1.11. ELI Lilly and Company
13.1.12. F. Hoffmann-La Roche Ltd
13.1.13. Gilead Sciences, Inc.
13.1.14. GlaxoSmithKline PLC
13.1.15. Ikena Oncology
13.1.16. Incyte Corporation
13.1.17. Johnson & Johnson Services, Inc.
13.1.18. Merck & Co., Inc.
13.1.19. Novartis AG
13.1.20. OSE Immunotherapeutics SA
13.1.21. Pfizer Inc.
13.1.22. QIAGEN N.V.
13.1.23. Sanofi SA
13.1.24. Seattle Genetics Inc.
13.1.25. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



List of Figures

FIGURE 1. CANCER IMMUNOTHERAPY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER IMMUNOTHERAPY DRUGS MARKET DYNAMICS
FIGURE 7. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. CANCER IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 11. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 18. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 34. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. MEXICO CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 48. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. CHINA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. JAPAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 76. THAILAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. DENMARK CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 88. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. EGYPT CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 91. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FINLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. ITALY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 112. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. NORWAY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 114. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 115. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. POLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 118. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. QATAR CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 129. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SPAIN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 139. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. TURKEY CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. CANCER IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 148. CANCER IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 149. CANCER IMMUNOTHERAPY DRUGS MARKET LICENSE & PRICING